Investigational drug · Phase 2
NNC0662-0419
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Diabetes Mellitus, Type 2, Overweight.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "NNC0662-0419"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC0662-0419", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Diabetes Mellitus, Type 2
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC0662-0419" as an intervention, largest first.
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07415954 · 270 participants (planned) · Start Apr 17, 2026 · Primary completion Sep 3, 2027
Drug: NNC0662-0419; Semaglutide and 1 more · For: Diabetes Mellitus, Type 2
Sites: Lancaster, California; Lomita, California; Long Beach, California · 63 sites in all
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07639021 · 233 participants · Start Jun 9, 2026 · Primary completion Jun 14, 2027
Drug: NNC0662-0419; Semaglutide and 2 more · For: Obesity
Sites: Montgomery, Alabama; Costa Mesa, California; Los Angeles, California · 25 sites in all
- A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07184632 · 224 participants · Start Oct 1, 2025 · Primary completion Dec 14, 2026
Drug: NNC0662-0419; Placebo · For: Overweight; Obesity
Sites: Tempe, Arizona; Lincoln, Nebraska
- A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06737536 · 100 participants · Start Dec 18, 2024 · Primary completion Jul 26, 2025
Drug: NNC0662-0419 · For: Overweight; Obesity
Sites: Lincoln, Nebraska
- A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07101783 · 100 participants · Start Aug 1, 2025 · Primary completion Oct 31, 2025
Drug: NNC0662-0419 · For: Overweight; Obesity
Sites: Cypress, California
- A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body WeightActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07525791 · 41 participants · Start Apr 7, 2026 · Primary completion May 2, 2027
Drug: NNC0662-0419; Oral contraceptive and 1 more · For: Overweight; Obesity
Sites: Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.